{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:10:08Z","timestamp":1792782608058,"version":"4.5.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Beijing Hospitals Authority \"Peak\" Talent Training Program","award":["DFL20240703"],"award-info":[{"award-number":["DFL20240703"]}]},{"name":"Capital Medical University Outstanding Young Talent Program","award":["A2310"],"award-info":[{"award-number":["A2310"]}],"id":[{"id":"https:\/\/ror.org\/013xs5b60","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Postdoctoral Innovation Talents Support Program","award":["BX20240234"],"award-info":[{"award-number":["BX20240234"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Radiol"],"DOI":"10.1007\/s00330-026-12716-z","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T16:26:30Z","timestamp":1786638390000},"page":"8236-8248","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["\u0394Average of long and short axis diameter on non-contrast CT is associated with major pathological response to neoadjuvant immunotherapy in resectable non-small cell lung cancer"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-0018-5803","authenticated-orcid":false,"given":"Jingyi","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunze","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianlin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinying","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,13]]},"reference":[{"key":"12716_CR1","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A (2024) Cancer statistics, 2024. CA Cancer J Clin 74:12\u201349","journal-title":"CA Cancer J Clin"},{"key":"12716_CR2","first-page":"394","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394\u2013424","journal-title":"CA Cancer J Clin"},{"key":"12716_CR3","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/S0140-6736(21)02098-5","volume":"398","author":"E Felip","year":"2021","unstructured":"Felip E, Altorki N, Zhou C et al (2021) Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet 398:1344\u20131357","journal-title":"Lancet"},{"key":"12716_CR4","doi-asserted-by":"publisher","first-page":"3525","DOI":"10.1158\/1078-0432.CCR-19-4180","volume":"26","author":"T Cascone","year":"2020","unstructured":"Cascone T, Sepesi B, Lin HY et al (2020) A phase I\/II study of neoadjuvant cisplatin, docetaxel, and nintedanib for resectable non-small cell lung cancer. Clin Cancer Res 26:3525\u20133536","journal-title":"Clin Cancer Res"},{"key":"12716_CR5","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1056\/NEJMoa1716078","volume":"378","author":"PM Forde","year":"2018","unstructured":"Forde PM, Chaft JE, Smith KN et al (2018) Neoadjuvant PD-1 blockade in resectable lung cancer. N Engl J Med 378:1976\u20131986","journal-title":"N Engl J Med"},{"key":"12716_CR6","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/S1470-2045(20)30140-6","volume":"21","author":"CA Shu","year":"2020","unstructured":"Shu CA, Gainor JF, Awad MM et al (2020) Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol 21:786\u2013795","journal-title":"Lancet Oncol"},{"key":"12716_CR7","doi-asserted-by":"publisher","first-page":"e42","DOI":"10.1016\/S1470-2045(13)70334-6","volume":"15","author":"MD Hellmann","year":"2014","unstructured":"Hellmann MD, Chaft JE, William WN Jr et al (2014) Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint. Lancet Oncol 15:e42\u2013e50","journal-title":"Lancet Oncol"},{"key":"12716_CR8","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s40425-018-0382-2","volume":"6","author":"JR Brahmer","year":"2018","unstructured":"Brahmer JR, Govindan R, Anders RA et al (2018) The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC). J Immunother Cancer 6:75","journal-title":"J Immunother Cancer"},{"key":"12716_CR9","first-page":"2495","volume":"36","author":"H Watanabe","year":"2009","unstructured":"Watanabe H, Okada M, Kaji Y et al (2009) [New response evaluation criteria in solid tumours\u2014revised RECIST guideline (version 1.1)]. Gan To Kagaku Ryoho 36:2495\u20132501","journal-title":"Gan To Kagaku Ryoho"},{"key":"12716_CR10","doi-asserted-by":"publisher","first-page":"4790","DOI":"10.1016\/j.cell.2024.06.038","volume":"187","author":"Y Yang","year":"2024","unstructured":"Yang Y, Chen X, Pan J et al (2024) Pan-cancer single-cell dissection reveals phenotypically distinct B cell subtypes. Cell 187:4790\u20134811.e4722","journal-title":"Cell"},{"key":"12716_CR11","doi-asserted-by":"publisher","first-page":"6625","DOI":"10.1007\/s00330-023-09922-4","volume":"33","author":"Y Cheng","year":"2023","unstructured":"Cheng Y, Chen ZY, Huang JJ, Shao D (2023) Efficacy evaluation of neoadjuvant immunotherapy plus chemotherapy for non-small-cell lung cancer: comparison of PET\/CT with postoperative pathology. Eur Radiol 33:6625\u20136635","journal-title":"Eur Radiol"},{"key":"12716_CR12","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1002\/mc.23883","volume":"64","author":"Y Geng","year":"2025","unstructured":"Geng Y, Yin T, Li Y et al (2025) Computed tomography-based radiomics and genomics analyses for survival prediction of stage III unresectable non-small cell lung cancer treated with definitive chemoradiotherapy and immunotherapy. Mol Carcinog 64:733\u2013743","journal-title":"Mol Carcinog"},{"key":"12716_CR13","first-page":"904","volume":"23","author":"J Li","year":"2020","unstructured":"Li J, Li X, Chen X, Ma S (2020) [Research advances and obstacles of CT-based radiomics in diagnosis and treatment of lung cancer]. Zhongguo Fei Ai Za Zhi 23:904\u2013908","journal-title":"Zhongguo Fei Ai Za Zhi"},{"key":"12716_CR14","doi-asserted-by":"publisher","first-page":"2696","DOI":"10.21037\/tlcr-2020-63","volume":"9","author":"W Liang","year":"2020","unstructured":"Liang W, Cai K, Chen C et al (2020) Expert consensus on neoadjuvant immunotherapy for non-small cell lung cancer. Transl Lung Cancer Res 9:2696\u20132715","journal-title":"Transl Lung Cancer Res"},{"key":"12716_CR15","doi-asserted-by":"publisher","first-page":"4160","DOI":"10.1111\/febs.15028","volume":"286","author":"J Zhang","year":"2019","unstructured":"Zhang J, Shi Z, Xu X, Yu Z, Mi J (2019) The influence of microenvironment on tumor immunotherapy. FEBS J 286:4160\u20134175","journal-title":"FEBS J"},{"key":"12716_CR16","doi-asserted-by":"publisher","first-page":"299","DOI":"10.21037\/qims.2017.06.05","volume":"7","author":"I Hidrovo","year":"2017","unstructured":"Hidrovo I, Dey J, Chesal ME, Shumilov D, Bhusal N, Mathis JM (2017) Experimental method and statistical analysis to fit tumor growth model using SPECT\/CT imaging: a preclinical study. Quant Imaging Med Surg 7:299\u2013309","journal-title":"Quant Imaging Med Surg"},{"key":"12716_CR17","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s40425-019-0513-4","volume":"7","author":"M Wang","year":"2019","unstructured":"Wang M, Chen C, Jemielita T et al (2019) Are tumor size changes predictive of survival for checkpoint blockade based immunotherapy in metastatic melanoma? J Immunother Cancer 7:39","journal-title":"J Immunother Cancer"},{"key":"12716_CR18","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1038\/s41591-021-01462-y","volume":"27","author":"BC Creelan","year":"2021","unstructured":"Creelan BC, Wang C, Teer JK et al (2021) Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial. Nat Med 27:1410\u20131418","journal-title":"Nat Med"},{"key":"12716_CR19","doi-asserted-by":"crossref","unstructured":"Waser NA, Quintana M, Schweikert B et al (2024) Pathological response in resectable non-small cell lung cancer: a systematic literature review and meta-analysis. JNCI Cancer Spectr 8:pkae021","DOI":"10.1093\/jncics\/pkae021"},{"key":"12716_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2020.100921","volume":"14","author":"J Hu","year":"2021","unstructured":"Hu J, Cui C, Yang W et al (2021) Using deep learning to predict anti-PD-1 response in melanoma and lung cancer patients from histopathology images. Transl Oncol 14:100921","journal-title":"Transl Oncol"},{"key":"12716_CR21","doi-asserted-by":"publisher","first-page":"204","DOI":"10.21037\/qims-19-998","volume":"11","author":"BW Zhang","year":"2021","unstructured":"Zhang BW, Zhang Y, Ye JD, Qiang JW (2021) Use of relative CT values to evaluate the invasiveness of pulmonary subsolid nodules in patients with emphysema. Quant Imaging Med Surg 11:204\u2013214","journal-title":"Quant Imaging Med Surg"},{"key":"12716_CR22","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/j.cell.2023.02.015","volume":"186","author":"D Wang","year":"2023","unstructured":"Wang D, Liu B, Zhang Z (2023) Accelerating the understanding of cancer biology through the lens of genomics. Cell 186:1755\u20131771","journal-title":"Cell"},{"key":"12716_CR23","doi-asserted-by":"publisher","first-page":"141","DOI":"10.21037\/tlcr-22-871","volume":"12","author":"G Zhao","year":"2023","unstructured":"Zhao G, Zhang H, Xu F et al (2023) Neoadjuvant pembrolizumab and chemotherapy in resectable clinical stage III non-small-cell lung cancer: a retrospective cohort study. Transl Lung Cancer Res 12:141\u2013149","journal-title":"Transl Lung Cancer Res"},{"key":"12716_CR24","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/s41416-025-02948-z","volume":"132","author":"X Lin","year":"2025","unstructured":"Lin X, Liu Z, Zhou K et al (2025) Intratumoral and peritumoral PET\/CT-based radiomics for non-invasively and dynamically predicting immunotherapy response in NSCLC. Br J Cancer 132:558\u2013568","journal-title":"Br J Cancer"},{"key":"12716_CR25","doi-asserted-by":"crossref","unstructured":"Janzen I, Ho C, Melosky B et al (2024) Machine learning and computed tomography radiomics to predict disease progression to upfront pembrolizumab monotherapy in advanced non-small-cell lung cancer: a pilot study. Cancers (Basel) 17:58","DOI":"10.3390\/cancers17010058"},{"key":"12716_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1414954","volume":"15","author":"G Ye","year":"2024","unstructured":"Ye G, Wu G, Zhang C et al (2024) CT-based quantification of intratumoral heterogeneity for predicting pathologic complete response to neoadjuvant immunochemotherapy in non-small cell lung cancer. Front Immunol 15:1414954","journal-title":"Front Immunol"},{"key":"12716_CR27","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1111\/j.1365-2125.2012.04179.x","volume":"73","author":"GV Goldmacher","year":"2012","unstructured":"Goldmacher GV, Conklin J (2012) The use of tumour volumetrics to assess response to therapy in anticancer clinical trials. Br J Clin Pharmacol 73:846\u2013854","journal-title":"Br J Clin Pharmacol"},{"key":"12716_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.currproblcancer.2024.101098","volume":"50","author":"F Wang","year":"2024","unstructured":"Wang F, Yang H, Chen W et al (2024) A combined model using pre-treatment CT radiomics and clinicopathological features of non-small cell lung cancer to predict major pathological responses after neoadjuvant chemoimmunotherapy. Curr Probl Cancer 50:101098","journal-title":"Curr Probl Cancer"},{"key":"12716_CR29","doi-asserted-by":"publisher","first-page":"2921","DOI":"10.1007\/s00330-015-4131-3","volume":"26","author":"Y Zhang","year":"2016","unstructured":"Zhang Y, Shen Y, Qiang JW, Ye JD, Zhang J, Zhao RY (2016) HRCT features distinguishing pre-invasive from invasive pulmonary adenocarcinomas appearing as ground-glass nodules. Eur Radiol 26:2921\u20132928","journal-title":"Eur Radiol"},{"key":"12716_CR30","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1148\/radiol.11100600","volume":"259","author":"F Fraioli","year":"2011","unstructured":"Fraioli F, Anzidei M, Zaccagna F et al (2011) Whole-tumor perfusion CT in patients with advanced lung adenocarcinoma treated with conventional and antiangiogenetic chemotherapy: initial experience. Radiology 259:574\u2013582","journal-title":"Radiology"},{"key":"12716_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-024-00765-w","volume":"8","author":"S Patkar","year":"2024","unstructured":"Patkar S, Chen A, Basnet A et al (2024) Predicting the tumor microenvironment composition and immunotherapy response in non-small cell lung cancer from digital histopathology images. NPJ Precis Oncol 8:280","journal-title":"NPJ Precis Oncol"},{"key":"12716_CR32","doi-asserted-by":"publisher","first-page":"S58","DOI":"10.1016\/j.jtho.2023.09.047","volume":"18","author":"S Wu","year":"2023","unstructured":"Wu S, Zhou H, Zhan W (2023) OA06.06 A novel multiparameter biomarker of pathological response for NSCLC receiving neoadjuvant immunotherapy: a real-world study. J Thorac Oncol 18:S58","journal-title":"J Thorac Oncol"},{"key":"12716_CR33","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/s41588-024-01998-y","volume":"57","author":"Y Yan","year":"2025","unstructured":"Yan Y, Sun D, Hu J et al (2025) Multi-omic profiling highlights factors associated with resistance to immuno-chemotherapy in non-small-cell lung cancer. Nat Genet 57:126\u2013139","journal-title":"Nat Genet"}],"container-title":["European Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-026-12716-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00330-026-12716-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-026-12716-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:03:19Z","timestamp":1791936199000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00330-026-12716-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,13]]},"references-count":33,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,11]]}},"alternative-id":["12716"],"URL":"https:\/\/doi.org\/10.1007\/s00330-026-12716-z","relation":{},"ISSN":["1432-1084"],"issn-type":[{"value":"1432-1084","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,13]]},"assertion":[{"value":"27 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The scientific guarantor of this publication is Xinying Xue.","order":1,"name":"Ethics","label":"Guarantor","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors of this manuscript declare no relationships with any companies whose products or services may be related to the subject matter of the article.","order":2,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"No complex statistical methods were necessary for this paper.","order":3,"name":"Ethics","label":"Statistics and biometry","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Written informed consent was waived by the Institutional Review Board.","order":4,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Institutional Review Board approval was obtained (number tky11-1x-2022(35)).","order":5,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"No study subjects or cohorts have been previously reported.","order":6,"name":"Ethics","label":"Study subjects or cohorts overlap","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"order":7,"name":"Ethics","label":"Methodology","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}}]}}